Merck (MRK) CMD 2024 summary

Strategic and Financial Outlook

• Organic sales growth guidance for 2024 is +2% to +5%, with net sales expected at €20.7–22.1bn and EBITDA pre at €5.8–6.4bn; H2 2024 is projected to be stronger than H1, driven by Life Science, Healthcare, and Electronics, especially AI-related semiconductors.

• All three business sectors—Life Science, Healthcare, and Electronics—are driving organic growth, with raised group guidance and upgraded midterm ambitions; Life Science targets a 7–9% mid-term organic sales CAGR, Electronics raises its mid-term organic sales CAGR aspiration to 5–9%, and Healthcare expects slight mid-term growth with long-term upside from innovation.

• Strategic acquisitions include Mirus Bio (bioprocessing) and UnitySC (3D metrology for AI); divestment of Surface Solutions sharpens portfolio focus on Electronics and innovation leadership.

• Capital allocation will shift to lower capital intensity post-2025, with capex guidance of €1.6–1.8bn for 2024, enhancing cash generation and supporting disciplined M&A, especially in Life Science.

• M&A remains focused on larger Life Science deals, external innovation in Healthcare, and bolt-on technology acquisitions in growth areas, with transformational deals considered only if strategic and financially disciplined.

Innovation, Sustainability, and Operational Excellence

• Innovation is central, with investments in novel modalities (ADCs, mRNA, VGTs), digitalization, and AI-driven solutions across all sectors to outpace market growth.

• Digital transformation and smart manufacturing initiatives are reducing costs, improving margins, and enabling scalable operations, with AI and data analytics embedded in business processes.

• Sustainability targets exceeded for water and waste reduction in 2023, with new goals to reduce water intensity by 50% and achieve a 70% circularity rate by 2030, and over 2,500 sustainable products developed in Life Science.

• Circular economy and supplier decarbonization programs are being implemented, with sector-specific roadmaps and KPIs to drive progress and competitive advantage.

• Diversity, equity, and inclusion efforts are advancing, with a goal of gender parity in leadership by 2030 and expanded health equity initiatives, embedding ESG principles across the value chain.

Sector-Specific Developments and Market Positioning

• Life Science is adapting to evolving post-COVID market dynamics, focusing on high-growth segments, innovation, and regional strategies, especially in Asia, with bioprocessing customers reaching target inventory and order intake improving.

• Healthcare growth is underpinned by Cardiometabolic & Endocrinology (CM&E), Fertility, and blockbuster products like Mavenclad and Erbitux, with external innovation targeted to comprise at least 50% of the pipeline.

• Electronics is positioned as a critical enabler of AI and advanced semiconductor technologies, with a broad portfolio and technology leadership in thin films, metrology, and materials for miniaturization and 3D densification, and growth propelled by AI-driven demand and recovery in memory and analog nodes.

• Sustainability and digitalization are integrated into product design and manufacturing, with collaborative industry partnerships to advance sustainable solutions.

• Merck has delivered a 5% organic sales CAGR and 8% total sales CAGR (including M&A) from FY09–23, with a 10% CAGR in EBITDA pre and 12% in EPS pre, driven by innovation, operational excellence, and disciplined capital allocation.